Market Cap 64.31M
Revenue (ttm) 322.20M
Net Income (ttm) -182.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -56.61%
Debt to Equity Ratio 0.00
Volume 391,223
Avg Vol 883,826
Day's Range N/A - N/A
Shares Out 98.75M
Stochastic %K 71%
Beta 1.02
Analysts Sell
Price Target $1.88

Company Profile

DocGo Inc. operates as a mobile healthcare services company in the United States and the United Kingdom. It operates through Mobile Health Services and Transportation Services segments. The company offers transportation services comprising emergency response services; and non-emergency transport services, such as ambulance and wheelchair transportation services. It also provides mobile health services through its care delivery platform that are performed at home, offices, and other locations com...

Industry: Medical Care Facilities
Sector: Healthcare
Phone: 844 443 6246
Website: docgo.com
Address:
685 Third Avenue, Suite 900, 9th Floor, New York, United States
amda
amda Jul. 20 at 4:44 PM
$DCGO she's gettin' frisky
0 · Reply
Lt_Val_Train
Lt_Val_Train Jul. 19 at 4:15 PM
$DCGO the company disclosed that stockholders approved a 1-for-5 to 1-for-10 reverse stock split, with the final ratio and timing left to the Board’s discretion. The split appears approved but not yet implemented. Public reports based on SEC filings also indicate that certain proposed charter amendments on corporate opportunities and officer liability did not receive the required stockholder approval. DocGo has also announced a review of strategic alternatives intended to maximize shareholder value. In my opinion, this may include a possible going-private transaction, but the company has not said that is the purpose of the review, and it should not be treated as confirmed. The Board of Directors generally has fiduciary duties to act in the best interests of the corporation and shareholders.
0 · Reply
Lynchador
Lynchador Jul. 19 at 11:12 AM
$DCGO Interesting things looking ahead to Q2: check how revenue behaves. It should be noted that, excluding migrants and SteadyMD, the growth that DocGo has experienced has been mostly from one quarter to this last one. It would be good to see how remote patient monitoring and phlebotomy behave, as well as the progress in assigned lives and clients requesting DocGo as a sole medical provider (only 1k in the first quarter, so there should be great progress here). ​In the second place, I am very interested in the progress with SG&A cuts, headcount reduction, and vendors for this Q, and to see how much it has been reduced prior to the large reduction in Q3. Also, to see how SteadyMD's performance continues (to see if seasonality reduces the progress or not) and finally transportation, although as long as revenue doesn't drop compared to Q1, it would already be very good. Also interesting is the cash position; I believe it shouldn't drop barely at all since they have collected about 8–9mil
0 · Reply
Nuclear_Elvis
Nuclear_Elvis Jul. 17 at 10:14 PM
$DCGO If you look at the Weekly Chart, it was a "2 Steps Forward, 1 Step Back" trading week, encouraging to see recovery from the All-Time Low after the Russell Index Exit selloff. As crazy as this may sound, I am less concerned about the Reverse Split potential as I am more interested in the upcoming Q2 Earnings Report. With this 10-Q and going forward, we begin to shed the prior NYC Healthcare historical data from being part of the conversation, and will eventually be totally free of that contrast, which helps the company look more like a traditional Growth Company on the rise. DocGo needs more stories about their progress and put all the controversial stories in the rear-view mirror (looking at you Capone, and NYC Contract). Looking forward - DocGo has a fully-owned Subsidiary named Steady MD - that is the primary provider and partner with $AMZN Amazon's healthcare arm, which - most Amazon investors may not even know the company is in the Virtual Healthcare business now.
0 · Reply
amda
amda Jul. 17 at 7:29 PM
$DCGO Lee, you have talked about exploring "Strategic Alternatives" - let's see that big buyout or partnership announcement!!! LFG you sh*thead
0 · Reply
amda
amda Jul. 17 at 7:24 PM
$DCGO come on Lee you sh*thead - lay that big news on us after the close!!
0 · Reply
amda
amda Jul. 17 at 7:23 PM
$DCGO some buyers coming in late - I'd love to see a strong finish - it would be a nice birthday present for me!
0 · Reply
amda
amda Jul. 17 at 6:27 PM
$DCGO a buyout of $DCGO by any of these huge insurance companies would make a lot of sense and could be easily made with merely their pocket change: $UNH $CVS $ELV
0 · Reply
amda
amda Jul. 17 at 5:50 PM
$DCGO $DCGO Nuclear Elvis -how about this edited version? Feel free to make your own edits and repost elsewhere as appropriate $DCGO for newcomers: DOCGO is not your typical penny stock. The company has $300 million in revenues. All government business has been written down to zero, so there is no further overhang. Legacy business lines are all growing and the new acquisition, Steady MD, is growing rapidly as a partner provider for Amazon's healthcare arm. The value of this relationship for $DCGO’s accelerating growth cannot be understated. Virtually NO DEBT and an extension of the stock buyback program has recently been announced. Company projects a return to profitability in the second half of 2026. With a market cap of LESS THAN 25% OF REVENUES, this represents a compelling opportunity imo. $UNH $CVS $ELV Bullish
1 · Reply
amda
amda Jul. 17 at 2:03 PM
$DCGO for newcomers: DOCGO is not your typical penny stock. The company has $300 million in revenues. All government business has been written down to zero, so there is no further overhang. Legacy business lines are all growing, and the new acquisition is growing rapidly. Virtually NO DEBT and an extension of the stock buyback program has recently been announced. Company projects a return to profitablilty in the second half of 2026. With a market cap of LESS THAN 25% OF REVENUES, this represents a compelling opportunity imo. $UNH $CVS $ELV
2 · Reply
Latest News on DCGO
DocGo Transcript: AGM 2026

Jun 16, 2026, 12:00 PM EDT - 4 weeks ago

DocGo Transcript: AGM 2026


DocGo launches mobile phlebotomy services in South Florida

2026-06-03T12:09:35.000Z - 6 weeks ago

DocGo launches mobile phlebotomy services in South Florida


DocGo Launches Mobile Phlebotomy Services in South Florida

Jun 3, 2026, 7:35 AM EDT - 6 weeks ago

DocGo Launches Mobile Phlebotomy Services in South Florida


DocGo reports Q1 EPS (15c), two estimates (6c)

2026-05-11T21:24:48.000Z - 2 months ago

DocGo reports Q1 EPS (15c), two estimates (6c)


DocGo Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

DocGo Earnings Call Transcript: Q1 2026


DocGo Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

DocGo Earnings release: Q1 2026


DocGo Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

DocGo Quarterly report: Q1 2026


DocGo Announces First Quarter 2026 Results

May 11, 2026, 4:05 PM EDT - 2 months ago

DocGo Announces First Quarter 2026 Results


DocGo Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 3 months ago

DocGo Proxy statement: Proxy filing


DocGo Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 3 months ago

DocGo Proxy statement: Proxy filing


DocGo Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

DocGo Proxy statement: Proxy filing


DocGo Slides: Investor presentation

Mar 25, 2026, 8:00 AM EDT - 4 months ago

DocGo Slides: Investor presentation


DocGo price target lowered to $1 from $1.50 at Canaccord

2026-03-25T10:40:21.000Z - 4 months ago

DocGo price target lowered to $1 from $1.50 at Canaccord


DocGo price target lowered to $2.50 from $4 at Stifel

2026-03-17T10:50:14.000Z - 4 months ago

DocGo price target lowered to $2.50 from $4 at Stifel


DocGo Earnings Call Transcript: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 4 months ago

DocGo Earnings Call Transcript: Q4 2025


DocGo Annual report: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 4 months ago

DocGo Annual report: Q4 2025


DocGo Earnings release: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 4 months ago

DocGo Earnings release: Q4 2025


DocGo reports FY25 EPS ($1.84), two estimates (60c)

2026-03-16T20:21:32.000Z - 4 months ago

DocGo reports FY25 EPS ($1.84), two estimates (60c)


DocGo Announces Fourth Quarter and Full Year 2025 Results

Mar 16, 2026, 4:05 PM EDT - 4 months ago

DocGo Announces Fourth Quarter and Full Year 2025 Results


DocGo Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 5 months ago

DocGo Transcript: TD Cowen 46th Annual Health Care Conference


DocGo Transcript: 28th Annual Needham Growth Conference Virtual

Jan 14, 2026, 1:30 PM EST - 6 months ago

DocGo Transcript: 28th Annual Needham Growth Conference Virtual


DocGo Transcript: IAccess Alpha Virtual MicroCap Conference

Dec 9, 2025, 1:00 PM EST - 7 months ago

DocGo Transcript: IAccess Alpha Virtual MicroCap Conference


DocGo Transcript: 17th Annual Southwest IDEAS Conference

Nov 19, 2025, 2:20 PM EST - 8 months ago

DocGo Transcript: 17th Annual Southwest IDEAS Conference


DocGo Announces Participation at Upcoming Investor Conferences

Nov 13, 2025, 7:35 AM EST - 8 months ago

DocGo Announces Participation at Upcoming Investor Conferences


DocGo Slides: Investor Presentation

Nov 12, 2025, 6:00 PM EST - 8 months ago

DocGo Slides: Investor Presentation


DocGo price target lowered to $1.50 from $1.60 at Canaccord

2025-11-12T12:06:31.000Z - 8 months ago

DocGo price target lowered to $1.50 from $1.60 at Canaccord


DocGo Earnings Call Transcript: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

DocGo Earnings Call Transcript: Q3 2025


DocGo Quarterly report: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

DocGo Quarterly report: Q3 2025


DocGo Earnings release: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

DocGo Earnings release: Q3 2025


DocGo reports Q3 EPS (28c) vs 5c last year

2025-11-10T21:11:52.000Z - 8 months ago

DocGo reports Q3 EPS (28c) vs 5c last year


DocGo narrows FY25 revenue view to $315M-$320M from $300M-$330M

2025-11-10T21:11:29.000Z - 8 months ago

DocGo narrows FY25 revenue view to $315M-$320M from $300M-$330M


DocGo sees FY26 revenue $280M-$300M, consensus $317.78M

2025-11-10T21:11:18.000Z - 8 months ago

DocGo sees FY26 revenue $280M-$300M, consensus $317.78M


DocGo Announces Third Quarter 2025 Results

Nov 10, 2025, 4:05 PM EST - 8 months ago

DocGo Announces Third Quarter 2025 Results


DocGo Transcript: M&A Announcement

Oct 21, 2025, 11:00 AM EDT - 9 months ago

DocGo Transcript: M&A Announcement


DocGo Press release: M&A Announcement

Oct 21, 2025, 11:00 AM EDT - 9 months ago

DocGo Press release: M&A Announcement


DocGo Slides: M&A Announcement

Oct 21, 2025, 11:00 AM EDT - 9 months ago

DocGo Slides: M&A Announcement


Why Is DocGo Stock (DCGO) Surging Today?

2025-10-21T11:26:30.000Z - 9 months ago

Why Is DocGo Stock (DCGO) Surging Today?


Closing Bell Movers: DocGo soars after SteadyMD deal

2025-10-20T22:50:33.000Z - 9 months ago

Closing Bell Movers: DocGo soars after SteadyMD deal

CCK FLR HTCR IBIO NEUP


DocGo acquires virtual care platform SteadyMD

2025-10-20T21:30:22.000Z - 9 months ago

DocGo acquires virtual care platform SteadyMD


DocGo Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 10:20 AM EDT - 11 months ago

DocGo Transcript: Cantor Global Healthcare Conference 2025


DocGo Transcript: 16th Annual Midwest Ideas Conference

Aug 26, 2025, 12:30 PM EDT - 11 months ago

DocGo Transcript: 16th Annual Midwest Ideas Conference


DocGo price target raised to $1.60 from $1.45 at Canaccord

2025-08-21T10:40:26.000Z - 11 months ago

DocGo price target raised to $1.60 from $1.45 at Canaccord


DocGo Announces Participation at Three Upcoming Conferences

Aug 18, 2025, 7:35 AM EDT - 1 year ago

DocGo Announces Participation at Three Upcoming Conferences


DocGo Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

DocGo Earnings Call Transcript: Q2 2025


DocGo Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

DocGo Quarterly report: Q2 2025


DocGo Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

DocGo Earnings release: Q2 2025


DocGo backs FY25 revenue view of $300M-$330M, consensus $.

2025-08-07T20:57:46.000Z - 1 year ago

DocGo backs FY25 revenue view of $300M-$330M, consensus $.


DocGo reports Q2 EPS (11c), consensus (23c)

2025-08-07T20:51:26.000Z - 1 year ago

DocGo reports Q2 EPS (11c), consensus (23c)


DocGo Announces Second Quarter 2025 Results

Aug 7, 2025, 4:05 PM EDT - 1 year ago

DocGo Announces Second Quarter 2025 Results


DocGo Transcript: AGM 2025

Jun 17, 2025, 12:00 PM EDT - 1 year ago

DocGo Transcript: AGM 2025


DocGo Slides: Investor Presentation

Jun 12, 2025, 9:00 AM EDT - 1 year ago

DocGo Slides: Investor Presentation


DocGo price target lowered to $4 from $6 at Northland

2025-05-12T13:02:04.000Z - 1 year ago

DocGo price target lowered to $4 from $6 at Northland


DocGo downgraded to Hold from Buy at Canaccord

2025-05-09T22:56:13.000Z - 1 year ago

DocGo downgraded to Hold from Buy at Canaccord


DocGo price target lowered to $4 from $5.50 at Stifel

2025-05-09T14:40:48.000Z - 1 year ago

DocGo price target lowered to $4 from $5.50 at Stifel


DocGo Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

DocGo Earnings Call Transcript: Q1 2025


DocGo Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

DocGo Quarterly report: Q1 2025


DocGo Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

DocGo Earnings release: Q1 2025


DocGo Announces First Quarter 2025 Results

May 8, 2025, 4:05 PM EDT - 1 year ago

DocGo Announces First Quarter 2025 Results


DocGo Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

DocGo Proxy statement: Proxy Filing


DocGo Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

DocGo Proxy statement: Proxy Filing


DocGo Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

DocGo Proxy statement: Proxy Filing


DocGo Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 11:10 AM EST - 1 year ago

DocGo Transcript: TD Cowen 45th Annual Healthcare Conference


DocGo Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

DocGo Earnings Call Transcript: Q4 2024


DocGo Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

DocGo Annual report: Q4 2024


DocGo Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

DocGo Earnings release: Q4 2024


DocGo Announces Fourth Quarter and Full-Year 2024 Results

Feb 27, 2025, 4:11 PM EST - 1 year ago

DocGo Announces Fourth Quarter and Full-Year 2024 Results


DocGo Transcript: 27th Annual Needham Growth Conference

Jan 15, 2025, 12:45 PM EST - 1 year ago

DocGo Transcript: 27th Annual Needham Growth Conference


DocGo Transcript: 2024 Southwest IDEAS Conference

Nov 20, 2024, 5:10 PM EST - 1 year ago

DocGo Transcript: 2024 Southwest IDEAS Conference


amda
amda Jul. 20 at 4:44 PM
$DCGO she's gettin' frisky
0 · Reply
Lt_Val_Train
Lt_Val_Train Jul. 19 at 4:15 PM
$DCGO the company disclosed that stockholders approved a 1-for-5 to 1-for-10 reverse stock split, with the final ratio and timing left to the Board’s discretion. The split appears approved but not yet implemented. Public reports based on SEC filings also indicate that certain proposed charter amendments on corporate opportunities and officer liability did not receive the required stockholder approval. DocGo has also announced a review of strategic alternatives intended to maximize shareholder value. In my opinion, this may include a possible going-private transaction, but the company has not said that is the purpose of the review, and it should not be treated as confirmed. The Board of Directors generally has fiduciary duties to act in the best interests of the corporation and shareholders.
0 · Reply
Lynchador
Lynchador Jul. 19 at 11:12 AM
$DCGO Interesting things looking ahead to Q2: check how revenue behaves. It should be noted that, excluding migrants and SteadyMD, the growth that DocGo has experienced has been mostly from one quarter to this last one. It would be good to see how remote patient monitoring and phlebotomy behave, as well as the progress in assigned lives and clients requesting DocGo as a sole medical provider (only 1k in the first quarter, so there should be great progress here). ​In the second place, I am very interested in the progress with SG&A cuts, headcount reduction, and vendors for this Q, and to see how much it has been reduced prior to the large reduction in Q3. Also, to see how SteadyMD's performance continues (to see if seasonality reduces the progress or not) and finally transportation, although as long as revenue doesn't drop compared to Q1, it would already be very good. Also interesting is the cash position; I believe it shouldn't drop barely at all since they have collected about 8–9mil
0 · Reply
Nuclear_Elvis
Nuclear_Elvis Jul. 17 at 10:14 PM
$DCGO If you look at the Weekly Chart, it was a "2 Steps Forward, 1 Step Back" trading week, encouraging to see recovery from the All-Time Low after the Russell Index Exit selloff. As crazy as this may sound, I am less concerned about the Reverse Split potential as I am more interested in the upcoming Q2 Earnings Report. With this 10-Q and going forward, we begin to shed the prior NYC Healthcare historical data from being part of the conversation, and will eventually be totally free of that contrast, which helps the company look more like a traditional Growth Company on the rise. DocGo needs more stories about their progress and put all the controversial stories in the rear-view mirror (looking at you Capone, and NYC Contract). Looking forward - DocGo has a fully-owned Subsidiary named Steady MD - that is the primary provider and partner with $AMZN Amazon's healthcare arm, which - most Amazon investors may not even know the company is in the Virtual Healthcare business now.
0 · Reply
amda
amda Jul. 17 at 7:29 PM
$DCGO Lee, you have talked about exploring "Strategic Alternatives" - let's see that big buyout or partnership announcement!!! LFG you sh*thead
0 · Reply
amda
amda Jul. 17 at 7:24 PM
$DCGO come on Lee you sh*thead - lay that big news on us after the close!!
0 · Reply
amda
amda Jul. 17 at 7:23 PM
$DCGO some buyers coming in late - I'd love to see a strong finish - it would be a nice birthday present for me!
0 · Reply
amda
amda Jul. 17 at 6:27 PM
$DCGO a buyout of $DCGO by any of these huge insurance companies would make a lot of sense and could be easily made with merely their pocket change: $UNH $CVS $ELV
0 · Reply
amda
amda Jul. 17 at 5:50 PM
$DCGO $DCGO Nuclear Elvis -how about this edited version? Feel free to make your own edits and repost elsewhere as appropriate $DCGO for newcomers: DOCGO is not your typical penny stock. The company has $300 million in revenues. All government business has been written down to zero, so there is no further overhang. Legacy business lines are all growing and the new acquisition, Steady MD, is growing rapidly as a partner provider for Amazon's healthcare arm. The value of this relationship for $DCGO’s accelerating growth cannot be understated. Virtually NO DEBT and an extension of the stock buyback program has recently been announced. Company projects a return to profitability in the second half of 2026. With a market cap of LESS THAN 25% OF REVENUES, this represents a compelling opportunity imo. $UNH $CVS $ELV Bullish
1 · Reply
amda
amda Jul. 17 at 2:03 PM
$DCGO for newcomers: DOCGO is not your typical penny stock. The company has $300 million in revenues. All government business has been written down to zero, so there is no further overhang. Legacy business lines are all growing, and the new acquisition is growing rapidly. Virtually NO DEBT and an extension of the stock buyback program has recently been announced. Company projects a return to profitablilty in the second half of 2026. With a market cap of LESS THAN 25% OF REVENUES, this represents a compelling opportunity imo. $UNH $CVS $ELV
2 · Reply
Valiums
Valiums Jul. 17 at 8:35 AM
$DCGO bullish. 1.2 ➡️1.5➡️ 2.2➡️2.5
0 · Reply
amda
amda Jul. 16 at 4:09 PM
$DCGO for newcomers: This is not your typical penny stock. The company has $300 million in revenues. All government business has been written down to zero, so there is no further overhang. Legacy business lines are all growing, and the new acquisition is growing rapidly. Virtually NO DEBT and an extension of the stock buyback program has recently been announced. Company projects a return to profitablilty in the second half of 2026. With a market cap of LESS THAN 25% OF REVENUES, this represents a compelling opportunity imo.
0 · Reply
amda
amda Jul. 16 at 2:30 PM
$DCGO time to call the Chinese pilots: Sum Ting Wong and Wi Tu Lo
0 · Reply
amda
amda Jul. 16 at 2:18 PM
$DCGO nice buying opportunity on this dip, imo...
0 · Reply
amda
amda Jul. 16 at 2:11 PM
$DCGO added under .66
0 · Reply
amda
amda Jul. 16 at 1:04 PM
$DCGO thanks for the post Nuclear - that's clear evidence that the float continues to decline.
0 · Reply
amda
amda Jul. 16 at 2:23 AM
$DCGO damn - I missed the $PYPL buyout. I'm damn sure not missing this $DCGO buyout.
2 · Reply
Nuclear_Elvis
Nuclear_Elvis Jul. 15 at 9:55 PM
$DCGO An Institution named Marquette Asset Management LLC just bought 338K Shares of DCGO, filed 13F with the SEC on July 10th. https://www.marketbeat.com/stocks/NASDAQ/DCGO/institutional-ownership/
0 · Reply
Nuclear_Elvis
Nuclear_Elvis Jul. 15 at 7:42 PM
$DCGO Always nice to see more Buying than Selling. Keep this up and you can throw away the charts, because weighted Buying always wins. Charts cannot prepare you for events such as - Share buybacks, nor Buyout Offers. There is no chart for those.
0 · Reply
amda
amda Jul. 15 at 5:20 PM
$DCGO the tussle at .70 should be resolved soon....
0 · Reply
amda
amda Jul. 14 at 6:49 PM
$DCGO adding every dip - like this one
0 · Reply
aamis
aamis Jul. 14 at 5:23 PM
$DCGO chart looks good on daily and weekly. Hopefully, we get strong ending for the day. My only concern is that based on notification they should keep the price above 1$ for 10 consecutive business days prior to 27Jul26. This means that they need to request 2nd compliance period and cannot simple meet the mininum bid price with RS.
2 · Reply